Frazier Life Sciences VIII, L.P. 4
4 · Arcutis Biotherapeutics, Inc. · Filed Feb 6, 2020
Insider Transaction Report
Form 4
Frazier Life Sciences VIII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-02-04+6,360,272→ 6,869,304 total - Conversion
Common Stock
2020-02-04+2,099,019→ 8,968,323 total - Conversion
Common Stock
2020-02-04+1,074,467→ 10,042,790 total - Purchase
Common Stock
2020-02-04$17.00/sh+500,000$8,500,000→ 10,542,790 total - Conversion
Series A Preferred Stock
2020-02-04−6,360,272→ 0 total→ Common Stock (6,360,272 underlying) - Conversion
Series B Preferred Stock
2020-02-04−2,099,019→ 0 total→ Common Stock (2,099,019 underlying) - Conversion
Series C Preferred Stock
2020-02-04−1,074,467→ 0 total→ Common Stock (1,074,467 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.